Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
I saw the proof right in front of me. After that, the decision was easy
What to Eat After IV Fluids Eat a balanced meal with lean protein, complex carbs, and healthy fats after your session
Curious about how Now Foods Glutathione supports cellular wellness? Check out our detailed blog post to learn about the powerful benefits of glutathione and why its a must-have for your health routine